文献速递头颈外科

FDG-PET/CT与病理在新诊断头颈癌中的研究:ACRIN 6685试验cN0 Neck结果

FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0.
PubMed 文献 · Otolaryngol Head Neck Surg · 2020-11-24

ACRIN 6685前瞻性非随机研究纳入287例初治头颈鳞癌患者,对至少一侧cN0颈进行清扫,术前FDG-PET/CT中心复核并与病理比较。共清扫983个淋巴结区(261侧颈,203例患者),报告了淋巴结转移发生率、相对风险、受累模式及对颈清扫的影响。结论:cN0患者同侧颈清扫中风险最高的淋巴结区为口腔癌的I区、咽癌的II区、喉癌的VI区。

要点

  • cN0头颈鳞癌同侧颈淋巴结转移风险最高区域:口腔癌I区、咽癌II区、喉癌VI区。
  • 研究基于FDG-PET/CT时代数据,报告了cN0患者淋巴结转移的发生率、位置和风险。
  • 治疗cN0患者时应考虑原发部位对应的最高风险淋巴结区。

核心结论

  • cN0头颈鳞癌同侧颈清扫中,淋巴结转移风险最高的区域为口腔癌的I区、咽癌的II区、喉癌的VI区。

研究设计与样本

  • 前瞻性非随机入组,纳入首次诊断头颈鳞癌且至少一侧cN0颈拟清扫的参与者,共287例入组。
  • 术前FDG-PET/CT中心复核并与病理比较,分析发生率、相对风险、淋巴结受累模式及对颈清扫的影响。
  • 共清扫983个淋巴结区(261侧颈,203例参与者)。

主要发现

  • 按原发部位和淋巴结区,同侧阳性淋巴结最高百分比:口腔癌I区17/110(15.5%),咽癌II区6/30(20.0%),喉癌VI区1/3(33.3%)。

关键数值与推荐

  • 口腔癌cN0同侧颈I区阳性淋巴结比例为17/110(15.5%)。
  • 咽癌cN0同侧颈II区阳性淋巴结比例为6/30(20.0%)。
  • 喉癌cN0同侧颈VI区阳性淋巴结比例为1/3(33.3%)。

临床怎么用

  • 治疗cN0头颈鳞癌患者时,应依据原发部位重点关注同侧颈最高风险淋巴结区:口腔癌I区、咽癌II区、喉癌VI区。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: FDG-PET/CT (fluorodeoxyglucose-positron emission tomography/computed tomography) is effective to assess for occult neck nodal disease. We report risks and patterns of nodal disease based on primary site and nodal level from data on the dissected cN0 per the results from ACRIN 6685. STUDY DESIGN: Prospective nonrandomized enrollment included participants with first-time head and neck squamous cell carcinoma and at least 1 cN0 neck side to be dissected. SETTING: Twenty-four ACRIN-certified centers internationally (American College of Radiology Imaging Network). METHODS: A total of 287 participants were enrolled. Preoperative FDG-PET/CT findings were centrally reviewed and compared with pathology. Incidence, relative risk, pattern of lymph node involvement, and impact upon neck dissection were reported. RESULTS: An overall 983 nodal levels were dissected (n = 261 necks, n = 203 participants). The highest percentages of ipsilateral positive nodes by primary location and nodal level were oral cavity (level I, 17/110, 15.5%), pharynx (level II, 6/30, 20.0%), and larynx (level VI, 1/3, 33.3%). CONCLUSION: Levels at greatest risk for nodal disease in cN0 in terms of ipsilateral neck dissection are level I (oral cavity), II (pharynx), and VI (larynx). These data should be considered when treating patients presenting with cN0. This is the first study to comprehensively report the incidence, location, and risk of metastases in cN0 in the FDG-PET/CT era.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Stack BC, Duan F, Subramaniam RM, et al. FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0. Otolaryngol Head Neck Surg. 2020. PMID: 33231504. doi:10.1177/0194599820969104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。